MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.braindev.2023.08.005

Медицинская библиотека · Brain & development · 2023

Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up.

Funato Michinori, Kino Atsunari, Iwata Reina, Yumioka Misaki, Yamashita Kohei, Urui Chika, Uno Ryoya, Kondo Emi, Morioka Etsuko, Ogawa Yoko, Kawamura Akihisa, Kusukawa Toshifumi, Minatsu Hiroshi

Клинический случайСтатьяПеревод в очереди

Аннотация

BACKGROUND

Spinal muscular atrophy (SMA) is a hereditary neuromuscular disorder characterized by skeletal muscle atrophy and weakness. New treatments for SMA have been developed namely, the drugs nusinersen, onasemnogene abeparvovec, and risdiplam. However, there are limited reports on their effects on adult patients with SMA, particularly over long periods. Therefore, this study aimed to determine the efficacy of nusinersen treatment in adult patients with SMA.

METHODS

We retrospectively reviewed patients with SMA type 2 or 3 who received nusinersen treatment between January 2018 and January 2023. All patients were evaluated using the Hammersmith Functional Motor Scale-Expanded (HFMSE) before the commencement of nusinersen treatment, and the change with respect to the baseline HFMSE score was compared.

RESULTS

A total of six patients, three patients each with SMA type 2 or 3, were treated with nusinersen. The median age of the patients before the commencement of nusinersen treatment was 51.5 years (range, 33-59 years), and the median treatment period was 50.5 months (range, 33-57 months). Three patients showed an increased tendency of improvement on the HFMSE at 15-26 months after nusinersen treatment, and the HFMSE score was maintained in two patients. Significant adverse events were observed in three patients: one subdural hematoma, one incidental bone fracture, and one cheek dermatofibrosarcoma.

CONCLUSIONS

Nusinersen treatment showed later efficacy in adult patients with SMA type 2 or 3. The distinct efficacy of nusinersen requires further investigation using a large number of cases and a long follow-up period.

Для цитирования: Funato Michinori, Kino Atsunari, Iwata Reina, Yumioka Misaki, Yamashita Kohei, Urui Chika, Uno Ryoya, Kondo Emi, Morioka Etsuko, Ogawa Yoko, Kawamura Akihisa, Kusukawa Toshifumi, Minatsu Hiroshi. Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up.. Brain & development. 2023. DOI: 10.1016/j.braindev.2023.08.005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.